ARPA-H awards $125M for manufacturing custom RNA therapies on demand

The US government has awarded $125 million to produce custom RNA therapies on demand. The money is going to a consortium led by Waterfall Scientific, which will focus on cell-free mRNA manufacturing. The award is part of a broader initiative by the Advanced Research Projects Agency for Health (ARPA-H) to fund biotech companies working on personalized RNA therapies. The ARPA-H is also funding a pilot project led by Harvard Medical School to develop a new class of RNA medicines. The award is notable for its size and the specific focus on on-demand manufacturing.

The funding is split between Waterfall Scientific and Harvard Medical School, with Waterfall Scientific receiving $54.5 million. The remaining $70.5 million will go to Harvard Medical School and other biotech companies involved in the initiative. The ARPA-H's investment in RNA therapies reflects a growing interest in personalized medicine, where treatments are tailored to individual patients based on their genetic makeup. The initiative aims to accelerate the development and manufacturing of RNA therapies, which have shown promise in treating a range of diseases, including cancer and genetic disorders. The award is not without its surprises.

The consortium led by Waterfall Scientific includes other biotech companies, but the specifics of their roles and contributions are not yet clear. The ARPA-H's decision to fund a pilot project led by Harvard Medical School, a well-established institution in the field of medicine, provides a counterpoint to the funding of Waterfall Scientific. The pilot project aims to develop a new class of RNA medicines, which could have broader implications for the field of personalized medicine.